Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BBIO
Nasdaq
2834
https://bridgebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BridgeBio Pharma Inc
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
- Apr 25th, 2024 2:02 pm
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Apr 10th, 2024 11:30 am
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Apr 7th, 2024 5:15 pm
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
- Mar 27th, 2024 1:25 pm
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
- Mar 6th, 2024 4:53 am
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
- Mar 5th, 2024 5:58 pm
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
- Mar 4th, 2024 9:17 pm
BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
- Mar 4th, 2024 9:05 pm
Bayer pays $310M to buy into BridgeBio heart drug
- Mar 4th, 2024 8:00 am
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
- Mar 4th, 2024 7:30 am
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
- Mar 4th, 2024 7:30 am
BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations
- Feb 24th, 2024 2:32 pm
BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
- Feb 22nd, 2024 1:40 pm
BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials
- Feb 22nd, 2024 12:52 pm
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
- Feb 22nd, 2024 12:30 pm
Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for
- Feb 15th, 2024 3:00 pm
Alnylam changes to heart drug trial spark doubts, sinking shares
- Feb 15th, 2024 11:54 am
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
- Feb 7th, 2024 12:34 pm
BridgeBio sells partial rights to dwarfism drug for $100M
- Feb 7th, 2024 12:22 pm
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Feb 5th, 2024 12:30 pm
Scroll